CO6351735A2 - Compuestos de azaindazol como antagonistas del receptor de ccr1 - Google Patents
Compuestos de azaindazol como antagonistas del receptor de ccr1Info
- Publication number
- CO6351735A2 CO6351735A2 CO11033549A CO11033549A CO6351735A2 CO 6351735 A2 CO6351735 A2 CO 6351735A2 CO 11033549 A CO11033549 A CO 11033549A CO 11033549 A CO11033549 A CO 11033549A CO 6351735 A2 CO6351735 A2 CO 6351735A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- ccr1
- recruitor
- azaindazol
- receiver
- Prior art date
Links
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 title abstract 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10040108P | 2008-09-26 | 2008-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6351735A2 true CO6351735A2 (es) | 2011-12-20 |
Family
ID=41349302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11033549A CO6351735A2 (es) | 2008-09-26 | 2011-03-17 | Compuestos de azaindazol como antagonistas del receptor de ccr1 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US7879873B2 (enExample) |
| EP (1) | EP2346868B1 (enExample) |
| JP (1) | JP5507567B2 (enExample) |
| KR (1) | KR20110060904A (enExample) |
| CN (1) | CN102227425A (enExample) |
| AP (1) | AP2739A (enExample) |
| AR (1) | AR073689A1 (enExample) |
| AU (1) | AU2009296839A1 (enExample) |
| BR (1) | BRPI0919844A2 (enExample) |
| CA (1) | CA2737472A1 (enExample) |
| CL (1) | CL2011000668A1 (enExample) |
| CO (1) | CO6351735A2 (enExample) |
| EA (1) | EA201100524A1 (enExample) |
| EC (1) | ECSP11010932A (enExample) |
| IL (1) | IL210857A0 (enExample) |
| MA (1) | MA32655B1 (enExample) |
| MX (1) | MX2011002951A (enExample) |
| NZ (1) | NZ591115A (enExample) |
| PE (1) | PE20110854A1 (enExample) |
| TW (1) | TW201018683A (enExample) |
| UA (1) | UA103634C2 (enExample) |
| UY (1) | UY32140A (enExample) |
| WO (1) | WO2010036632A1 (enExample) |
| ZA (1) | ZA201100625B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722923C (en) | 2008-04-29 | 2016-08-02 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| AP2739A (en) | 2008-09-26 | 2013-09-30 | Boehringer Ingelheim Int | Azaindazole compounds as CCRI receptor antagonists |
| US20100317646A1 (en) * | 2009-03-19 | 2010-12-16 | Medical Research Council Technology | Compounds |
| PL2491028T3 (pl) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1 |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| PH12012501153A1 (en) * | 2009-12-08 | 2012-10-22 | Boehringer Ingelheim Int | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| EP2388260A1 (de) * | 2010-05-21 | 2011-11-23 | Archimica GmbH | Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors |
| CN103384668B (zh) | 2010-09-03 | 2017-05-31 | 福马Tm有限责任公司 | 用于抑制nampt的化合物和组合物 |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
| JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| CN102775365A (zh) * | 2011-05-10 | 2012-11-14 | 无锡立诺康医药科技有限公司 | 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺 |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| EP2771011A4 (en) * | 2011-10-24 | 2015-04-15 | Glaxosmithkline Ip No 2 Ltd | CHEMICAL COMPOUNDS |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| US9458172B2 (en) * | 2012-03-02 | 2016-10-04 | Kenneth W Bair | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
| AR091858A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| US9776996B2 (en) * | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| FR3016879A1 (fr) * | 2014-01-29 | 2015-07-31 | Guillaume Laconde | Procede de preparation de benzotriazole n-acyles |
| TR201809388T4 (tr) | 2014-03-17 | 2018-07-23 | Pfizer | Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri. |
| UA120094C2 (uk) | 2014-04-14 | 2019-10-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Сполуки як модулятори ror-гамма |
| JP6810988B2 (ja) | 2015-10-23 | 2021-01-13 | ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ | 新規なフェロポーチン阻害剤 |
| BR112018009566A2 (pt) | 2015-11-13 | 2018-11-06 | Basf Se | compostos, mistura, composição agroquímica, uso de compostos e método para combater fungos nocivos fitopatogênicos |
| US20180354921A1 (en) | 2015-11-13 | 2018-12-13 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| CA3016068C (en) | 2016-03-07 | 2024-02-27 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| TWI853814B (zh) | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| CN111393376B (zh) * | 2020-05-11 | 2022-05-13 | 安徽赛迪生物科技有限公司 | 一种2-氯嘧啶-4-甲酸的合成方法 |
| WO2021262878A1 (en) * | 2020-06-24 | 2021-12-30 | Oregon Health & Science University | Novel molecule for modulation of innate immune responses controlled by sting protein |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| US4999363A (en) | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| RU2119920C1 (ru) | 1991-03-28 | 1998-10-10 | Эйсай Ко., Лтд. | Гетероцикло-циклические производные аминов или их фармацевтически приемлемые соли, промежуточные соединения, фармацевтическая композиция, способ ингибирования холинэстеразы, способ получения соединений |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| WO1994001415A1 (fr) | 1992-07-03 | 1994-01-20 | Kumiai Chemical Industry Co., Ltd. | Derive heterocyclique condense et desherbant |
| EP0657450B1 (en) | 1993-06-25 | 1998-09-09 | KumaiI Chemical Industry Co., Ltd. | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof |
| CA2207201A1 (en) | 1994-12-06 | 1996-06-13 | Caroline Henry | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| NZ503995A (en) | 1997-11-04 | 2003-02-28 | Pfizer Prod Inc | Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
| AU5895500A (en) | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| ATE455104T1 (de) | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
| US20090286791A1 (en) | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
| US7294624B2 (en) * | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
| EP1497278B1 (en) | 2002-04-11 | 2010-05-26 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic amide derivatives as cytokine inhibitors |
| TW200406385A (en) | 2002-05-31 | 2004-05-01 | Eisai Co Ltd | Pyrazole compound and pharmaceutical composition containing the same |
| ES2329356T3 (es) * | 2002-06-12 | 2009-11-25 | Chemocentryx, Inc. | Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias. |
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| EP1664052B1 (en) | 2003-08-15 | 2009-02-18 | AstraZeneca AB | Fused heterocycles as inhibitors of glutamate racemase (muri) |
| CA2598531A1 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
| GB0504828D0 (en) * | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| AU2006247136C1 (en) | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| ES2543714T3 (es) * | 2005-06-22 | 2015-08-21 | Chemocentryx, Inc. | Compuestos de azaindazol y métodos de uso |
| JP5155864B2 (ja) | 2005-09-01 | 2013-03-06 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−アリールアルキルアミノ−２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
| JP2009513677A (ja) | 2005-10-25 | 2009-04-02 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| TW200829578A (en) * | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| CN101743242A (zh) * | 2007-06-29 | 2010-06-16 | 苏尼西斯制药有限公司 | 用作raf激酶抑制剂的杂环化合物 |
| KR20100045480A (ko) | 2007-08-10 | 2010-05-03 | 크리스탈지노믹스(주) | 피리딘 유도체 및 이들의 사용방법 |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| WO2009085256A1 (en) * | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| CA2722923C (en) | 2008-04-29 | 2016-08-02 | Boehringer Ingelheim International Gmbh | Indazole compounds as ccr1 receptor antagonists |
| EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
| AP2739A (en) | 2008-09-26 | 2013-09-30 | Boehringer Ingelheim Int | Azaindazole compounds as CCRI receptor antagonists |
| PL2491028T3 (pl) | 2009-10-21 | 2014-05-30 | Boehringer Ingelheim Int | Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1 |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| PH12012501153A1 (en) | 2009-12-08 | 2012-10-22 | Boehringer Ingelheim Int | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
-
2009
- 2009-09-22 AP AP2011005685A patent/AP2739A/xx active
- 2009-09-22 WO PCT/US2009/057778 patent/WO2010036632A1/en not_active Ceased
- 2009-09-22 EA EA201100524A patent/EA201100524A1/ru unknown
- 2009-09-22 JP JP2011529154A patent/JP5507567B2/ja active Active
- 2009-09-22 CN CN2009801472064A patent/CN102227425A/zh active Pending
- 2009-09-22 MX MX2011002951A patent/MX2011002951A/es active IP Right Grant
- 2009-09-22 US US12/564,129 patent/US7879873B2/en active Active
- 2009-09-22 UA UAA201105061A patent/UA103634C2/ru unknown
- 2009-09-22 BR BRPI0919844A patent/BRPI0919844A2/pt not_active IP Right Cessation
- 2009-09-22 AU AU2009296839A patent/AU2009296839A1/en not_active Abandoned
- 2009-09-22 NZ NZ591115A patent/NZ591115A/xx not_active IP Right Cessation
- 2009-09-22 PE PE2011000789A patent/PE20110854A1/es not_active Application Discontinuation
- 2009-09-22 KR KR1020117006720A patent/KR20110060904A/ko not_active Withdrawn
- 2009-09-22 EP EP09792818.8A patent/EP2346868B1/en active Active
- 2009-09-22 CA CA2737472A patent/CA2737472A1/en not_active Abandoned
- 2009-09-24 UY UY0001032140A patent/UY32140A/es not_active Application Discontinuation
- 2009-09-25 AR ARP090103709A patent/AR073689A1/es unknown
- 2009-09-25 TW TW098132530A patent/TW201018683A/zh unknown
-
2010
- 2010-12-16 US US12/969,753 patent/US8063065B2/en active Active
-
2011
- 2011-01-25 ZA ZA2011/00625A patent/ZA201100625B/en unknown
- 2011-01-25 IL IL210857A patent/IL210857A0/en unknown
- 2011-03-17 CO CO11033549A patent/CO6351735A2/es active IP Right Grant
- 2011-03-24 MA MA33724A patent/MA32655B1/fr unknown
- 2011-03-25 CL CL2011000668A patent/CL2011000668A1/es unknown
- 2011-03-29 EC EC2011010932A patent/ECSP11010932A/es unknown
- 2011-10-14 US US13/273,509 patent/US8163918B2/en active Active
-
2012
- 2012-02-08 US US13/368,397 patent/US8338610B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL210857A0 (en) | 2011-04-28 |
| ECSP11010932A (es) | 2011-04-29 |
| UY32140A (es) | 2010-04-30 |
| MA32655B1 (fr) | 2011-09-01 |
| US8063065B2 (en) | 2011-11-22 |
| MX2011002951A (es) | 2011-04-26 |
| NZ591115A (en) | 2012-10-26 |
| AP2011005685A0 (en) | 2011-04-30 |
| US20110086846A1 (en) | 2011-04-14 |
| AU2009296839A1 (en) | 2010-04-01 |
| AP2739A (en) | 2013-09-30 |
| US8163918B2 (en) | 2012-04-24 |
| EP2346868B1 (en) | 2016-01-27 |
| US7879873B2 (en) | 2011-02-01 |
| JP5507567B2 (ja) | 2014-05-28 |
| UA103634C2 (en) | 2013-11-11 |
| EP2346868A1 (en) | 2011-07-27 |
| ZA201100625B (en) | 2011-09-28 |
| US20120035370A1 (en) | 2012-02-09 |
| TW201018683A (en) | 2010-05-16 |
| CL2011000668A1 (es) | 2011-10-28 |
| PE20110854A1 (es) | 2011-12-23 |
| CN102227425A (zh) | 2011-10-26 |
| AR073689A1 (es) | 2010-11-24 |
| US20120136158A1 (en) | 2012-05-31 |
| JP2012503664A (ja) | 2012-02-09 |
| BRPI0919844A2 (pt) | 2019-09-24 |
| WO2010036632A1 (en) | 2010-04-01 |
| CA2737472A1 (en) | 2010-04-01 |
| KR20110060904A (ko) | 2011-06-08 |
| US20100093724A1 (en) | 2010-04-15 |
| EA201100524A1 (ru) | 2011-10-31 |
| US8338610B2 (en) | 2012-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351735A2 (es) | Compuestos de azaindazol como antagonistas del receptor de ccr1 | |
| MX388468B (es) | Compuestos multicíclicos y métodos de uso de los mismos. | |
| UY30917A1 (es) | Moduladores 2-aminopiridina del receptor histamina h | |
| SV2011003807A (es) | Composiciones y metodos de uso para anticuerpos terapeuticos | |
| CO6541572A2 (es) | Octahidropirrolo[3.4-c]pirrolos distituidos como moduladores del receptor de orexina | |
| AR068354A1 (es) | Anticuerpos contra el receptor del linfona de burkitt (anti- cxcr5) humanizados, derivados de los mismos y su uso | |
| CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
| GT201400102A (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| ECSP11011517A (es) | Compuestos antivirales | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| CL2008001099A1 (es) | Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras. | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| CO6410295A2 (es) | Derivados de indol como antagonistas del receptor crth2 | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| PE20151144A1 (es) | Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias | |
| UY30479A1 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4 | |
| ECSP10010675A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina | |
| CL2009000116A1 (es) | Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable. | |
| CL2011001427A1 (es) | Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras. | |
| UY31340A1 (es) | Moduladores tieno- y furo-pirimidina del receptor de histamina h4 | |
| ECSP12011904A (es) | Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1. | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| CL2011002617A1 (es) | Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros. | |
| ECSP11010807A (es) | Sales de los compuestos del inhibidor de vih |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |